bazedoxifene

Bazedoxifene acetate (WAY-TES 424) is a novel selective estrogen receptor modulator (SERM).

Bazedoxifene is a non-steroidal, orally active selective estrogen receptor modulator that exhibits activity against ERα and ERβ with IC50 values of 26 nM and 99 nM, respectively. Bazedoxifene also inhibits IL-6/GP130 protein interactions. Bazedoxifene is utilized in research on postmenopausal osteoporosis and pancreatic cancer, serving as a dual-purpose compound for hormonal and cytokine pathway investigations.

Bazedoxifene hydrochloride (TSE 424 hydrochloride) is an orally active, selective, and potent estrogen receptor modulator (SERM) that crosses the blood-brain barrier and is an inhibitor of IL-6/GP130 protein interactions with high affinity for ERα and ERβ. It has a high affinity for ERα and ERβ and can be used to study postmenopausal osteoporosis and vasodilator-related diseases.

Bazedoxifene bis-β-D-glucuronide is a biochemical reagent used in glycobiology research. Glycobiology examines the structure, synthesis, biology, and evolution of sugars, encompassing carbohydrate chemistry, the enzymology of glycan formation and degradation, protein-glycan recognition, and the role of glycans in biological systems. This field is closely linked to fundamental research, biomedicine, and biotechnology.

GP130-IN-1 (compound 49) is an effective inhibitor of GP130, demonstrating significant in vitro anti-tumor activity and higher selectivity compared to Bazedoxifene. It induces ultrastructural changes in cells, leading to a time-dependent arrest of the cell cycle at the G0 G1 phase, and triggers both apoptosis and autophagy. GP130-IN-1 is useful for research on triple-negative breast cancer.